Interleukin-10 Inhibited the Expression of Tumor Antigens and Major Histocompatibility Complex Antigen on EJ-ras Oncogene Transformants

Publisher Website
Google Scholar
Abstract
Interleukin‐10 (IL‐10), a novel inhibitory cytokine, is one of Th‐2 (T helper) cytokine. It inhibits mixed lymphocyte reaction, and the production of inflammatory cytokine and monokine downregulates major histocompatibility complex antigen (MHC) class II antigen expression. However, the effect of IL‐10 on tumor cells is not known. Therefore, the mechanism of tumor tolerance induced by IL‐10 was investigated. (WKA rat fetus‐derived fibroblast) (WFB) and W14 and W31 (EJ‐ras oncogene transformants of WFB) were cultured with recombinant human (rh)IL‐10 (0, 10, 50, 100 ng/ml). FACS analysis was performed using the following monoclonal antibodies: anti‐rat MHC class I monoclonal antibody; and monoclonal antibody 109 (anti‐natural killer [NK] target molecule on W14). Monoclonal antibody (mAb) 109‐defined antigens were newly expressed during the transforming process by EJ‐ras oncogene transfection to WFB. In addition, the effects of rhIL‐10 on the ability of proliferation and susceptibility to NK cells were assessed. The cultivation with rhIL‐10 resulted in a dose‐dependent decrease in the expressions of MHC class I antigen and monoclonal antibody 109‐defined antigen. The proliferation and susceptibility to NK cells of W14 were inhibited. These data demonstrated a possibility that IL‐10 could induce tumor tolerance to host immunity by inhibiting the expression of tumor‐associated antigens and MHC class I.